The Aperlena Verdict
Open raceNo supplier dominates: 34 different companies have won the last 39 comparable contracts from this buyer over 5 years. This is a genuinely open race.
Based on 39 comparable awards by this buyer in this sector over 5 years. Every verdict is recorded before the outcome and graded against the award notice. How we score ourselves.
Summary
Machine-generated summaryThe GWQ ServicePlus AG, acting on behalf of its shareholder and customer statutory health insurance funds, intends to conclude non-exclusive rebate agreements under Section 130a(8) SGB V for the active substance Filgrastim, starting on 01.01.2026. Any interested pharmaceutical company may join the agreement at any time during its term under the same conditions (open-door admission model). Signed contracts, along with evidence of pharmaceutical marketing authorisation, must be submitted by 10.12.2025 to enable first reporting to the health insurers as of 01.01.2026. Documents, participating funds and deadlines are available on the GWQ award portal.
Description
Bid or no-bid?
Six questions before you commit a team. Under each one, what the register holds on it. The answers are yours.
Can I bid?
- Open procedure: any interested supplier may submit a bid. Above the EU threshold: open to companies from any EU country.
- The notice is written in German.
- Certificates from another EU country? Check the equivalents on eCertis
Official source
Source: TED - Tenders Electronic Daily (Publications Office of the EU)
Always verify details on the official notice.
Report an error in this notice
Last verified against TED - Tenders Electronic Daily (Publications Office of the EU) 6 days ago
What this buyer has paid before
Based on 22 comparable contracts this buyer awarded in this sector over the last 4 years.
- Median award
- €1
- Middle half of past awards
- €1 to €1
TED - Tenders Electronic Daily (Publications Office of the EU) publishes no value for this notice, so it has no mark on the scale. The official documents may state one.
Most recent awards
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 a Abs. 8 SGB V zu dem Präparat mit dem Wirkstoff Efbemalenograstim alfa (Ryzneuta)
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 c SGB V zu dem Präparat mit dem Wirkstoff Galcanezumab (Emgality)
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 c SGB V zu dem Präparat mit dem Wirkstoff Edoxaban (Lixiana)
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 a Abs. 8 SGB V und §130 c SGB V zu den Präparat mit dem Wirkstoff Depemokimab
- Arzneimittel - Bekanntmachung vergebener Aufträge nach §130 c SGB V zu dem Präparat Dolutegravir (Tivicay)
Award values as published by the official sources. Use them as a guide, not a rule: scope, lots and duration differ between contracts.
The buyer
Full buyer profileGWQ ServicePlus AG
- notices in the register
- 96
- awards
- 39
Who wins its contracts
Many suppliers- different companies won its awards
- 34
- of the awards went to the three most frequent winners
- 15%
- of its calls state an estimated value
- 0%
Based on 39 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners.
Competition
- tenders per lot on average (open and restricted procedures)
- 3.5
- of those lots received a single tender
- 13%
- of the awards went to companies based in another country
- 6%
As the official award notices state them, over the last 3 years. Tenders per lot count open and restricted procedures only: in a negotiated procedure or a direct award a single tender is the procedure itself. The country is the one the notice gives for the winner.
Who usually wins this buyer's contracts in this sector
Based on 39 awards with a linked company profile over the last 5 years.
39 open tenders right now
- Medicines - Conclusion of non-exclusive rebate agreements under Section 130a(8) SGB V for the active substance Aflibercept 40mg/ml 30 days left
- Medicines - Conclusion of non-exclusive discount agreements under Section 130a (8) SGB V from 01.02.2026 60 days left
- Medicines - Conclusion of non-exclusive discount agreements under § 130a para. 8 SGB V for the active ingredient Budesonide in the dosage form HKM 211 days left
Market context
TED - Tenders Electronic Daily (Publications Office of the EU) publishes no value for this notice, so it cannot be placed among the open notices of its sector. The official documents may state one.
- open now in Medical equipment & pharmaceuticals
- 8,327
- median open notice
- €250,709
Who wins in this market
Many suppliersGermany · Medical equipment & pharmaceuticals
- different companies won awards here
- 814
- of the awards went to the three most frequent winners
- 9%
- buyers awarded contracts here
- 445
Based on 1,521 awards with a named winner over the last 3 years. Counted by award, not by value, because lot and framework amounts are not comparable. Concentrated means the three most frequent winners took 65% or more of the awards; many suppliers, under 35% with at least ten different winners.
Competition
- tenders per lot on average (open and restricted procedures)
- 12.2
- of those lots received a single tender
- 16%
- of the awards went to companies based in another country
- 7%
- of the tenders came from another country
- 6%
As the official award notices state them, over the last 3 years. Tenders per lot count open and restricted procedures only: in a negotiated procedure or a direct award a single tender is the procedure itself. The country is the one the notice gives for the winner.
Similar tenders
Open now
Awarded before
Never miss a tender like this
62 new notices in Medical equipment & pharmaceuticals in Germany in the last 7 days. Get an email when new ones appear. Free.
Set up my alertOr follow just its CPV code, Pharmaceutical products: an email when new tenders arrive under it, no account needed.